➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Last Updated: July 23, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,034,867

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,034,867 protect, and when does it expire?

Patent 9,034,867 protects ARISTADA and is included in one NDA.

This patent has thirty-eight patent family members in twenty-two countries.

Summary for Patent: 9,034,867

Title:	Pharmaceutical compositions comprising sorbitan esters
Abstract:	The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs.
Inventor(s):	Perry; Jason M. (Cambridge, MA), Deaver; Daniel R. (Franklin, MA), Hickey; Magall B. (Medford, MA), Remenar; Julius F. (Waltham, MA), Vandiver; Jennifer (Arlington, MA)
Assignee:	ALKERMES PHARMA IRELAND LIMITED (Dublin, IE)
Application Number:	13/423,606
Patent Claim Types: see list of patent claims	Composition; Compound; Delivery; Use;

Drugs Protected by US Patent 9,034,867

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-001	Oct 5, 2015		RX	Yes	No	⤷ Try it Free	⤷ Try it Free	Y			TREATMENT OF SCHIZOPHRENIA	⤷ Try it Free
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-002	Oct 5, 2015		RX	Yes	No	⤷ Try it Free	⤷ Try it Free	Y			TREATMENT OF SCHIZOPHRENIA	⤷ Try it Free
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-003	Oct 5, 2015		RX	Yes	Yes	⤷ Try it Free	⤷ Try it Free	Y			TREATMENT OF SCHIZOPHRENIA	⤷ Try it Free
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-004	Jun 5, 2017		RX	Yes	No	⤷ Try it Free	⤷ Try it Free	Y			TREATMENT OF SCHIZOPHRENIA	⤷ Try it Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,034,867

Subscribe to access the full database, or Try it Free
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2012231160	⤷ Try it Free
Australia	2017204486	⤷ Try it Free
Australia	2019202633	⤷ Try it Free
Australia	2020250309	⤷ Try it Free
Brazil	112013023847	⤷ Try it Free
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey

Baxter

Mallinckrodt

Medtronic

Boehringer Ingelheim

Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.